Dollar Holds Near Two-Month High as Yen Approaches 160 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Google promotes ‘teacher approved’ apps for kids. Here’s what parents should know 
What is Zionism? The different meanings of a contested term 
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Why have so few atrocities ever been recognised as genocide? 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Meta Found Liable in New Mexico Facebook Data Privacy Case 
Why financial hardship is more likely if you’re disabled or sick 
Add as a preferred source on Google
Oncologica has launched its Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer.
A significant proportion of men, particularly those people who develop aggressive life-threatening prostate cancer at a relatively early age, can now be identified as a consequence that they carry inherited abnormal disease-causing genes.
The family of inherited prostate cancer-causing genes is all involved in a process called DNA damage repair (DDR) which plays a critical role in ensuring that the DNA in your cells is maintained in a healthy state.
An inherited abnormality in any of these DDR genes predisposes men to the development of early aggressive prostate cancer. Notably, survival among men with faulty DNA repair genes is half that of men with normal DDR genes.
The new genetic Prostatefocus genetic screening test uses a simple saliva self-sample collection kit. Men who test positive can then benefit from regular checks, blood tests, and lifestyle preventative measures.
Dr. Marco Loddo, co-owner and scientific director at Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, said that prostate cancer tends to grow slowly without symptoms, so men often present late with an advanced incurable disease.
Prostate cancer is more treatable when caught early so screening tests can help identify an individual at high risk of developing the disease so regular checks can take place.
The Prostatefocus test is available via Oncologica’s nationwide specialist medical healthcare providers who conduct a pre-test consultation explaining how the test works and the implications of any results.
